Literature DB >> 10413750

Ultrasound-guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with a 'cooled-tip needle'. A preliminary clinical experience.

G Francica1, G Marone.   

Abstract

OBJECTIVE: Radiofrequency hyperthermia using the newly-developed 'cooled-tip' needle has recently been proposed as a therapeutic modality for hepatocellular carcinoma (HCC). Herein we report our preliminary results on feasibility and effectiveness of the thermal ablation of mono- or pauci-focal hepatocellular carcinoma with the cooled-tip needle.
MATERIALS AND METHODS: We treated 15 cirrhotic patients (mean age 68.8 years; 12 males; 14 HCV-positive; 13 in Child's Class A and 2 in Class B) with 20 hepatocellular carcinoma nodules (mean diameter 28.1 mm; range 10-43 mm; nine lesions with diameter greater than 3 cm). None of the patients had portal thrombosis and/or extrahepatic spread. We used a radiofrequency generator (100 W of power) connected to a 18 g perfusion electrode needle with an exposed tip of 2-3 cm. The circuit was closed through a dispersive electrode positioned under the patient's thighs. A peristaltic pump infused a chilled (2-5 degrees C) saline solution to guarantee the continuous cooling of the needle tip. The needle was placed into target lesions under US guidance. The interventional procedure was carried out in general anesthesia without intubation. Dynamic helical CT was carried out 15-20 days after thermal ablation to assess therapeutic efficacy.
RESULTS: In all, 38 areas of coagulation necrosis (at 1000-1200 mA for 10-15 min) were generated in 24 sessions in the 20 hepatocellular carcinoma nodules (mean 1.9 lesions per nodule and 1.2 sessions per nodule). Complete necrosis as assessed at dynamic CT (lack of enhancement during the arteriographic phase) was achieved in 75% of cases in a single session; after a second RF session success rate was 90% (18 out of 20 nodules). A self-limited pleurisy along with a 5-fold increase in transaminases occurred in one patient; a 3-fold elevation of transaminases was encountered in three other patients. During the follow-up (median 15 months) five patients had recurrent hepatocellular carcinoma with a 1-year disease free interval of 64%. Of the three recorded deaths, two were due to intrahepatic tumor diffusion.
CONCLUSIONS: In our experience radiofrequency hyperthermia with the cooled-tip needle afforded an effective and safe percutaneous ablative method for HCC in cirrhosis and shortened treatment time.

Entities:  

Mesh:

Year:  1999        PMID: 10413750     DOI: 10.1016/s0929-8266(99)00022-1

Source DB:  PubMed          Journal:  Eur J Ultrasound        ISSN: 0929-8266


  20 in total

Review 1.  Ablative therapy for liver tumours.

Authors:  E A Dick; S D Taylor-Robinson; H C Thomas; W M W Gedroyc
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

2.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

3.  Fatal bile pulmonary embolism after radiofrequency treatment of a hepatocellular carcinoma.

Authors:  C Schmidt-Mutter; T Breining; A Gangi; E Canela; I Jourdan; D Mutter; J-P Dupeyron
Journal:  Surg Endosc       Date:  2003-10-28       Impact factor: 4.584

Review 4.  Radiofrequency thermal ablation of liver tumors.

Authors:  Elisabetta Buscarini; Agostino Savoia; Gianfranco Brambilla; Fernanda Menozzi; Luigi Reduzzi; Deike Strobel; Johannes Hänsler; Luigi Buscarini; Luigi Gaiti; Alessandro Zambelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

Review 5.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

6.  Percutaneous ethanol injection, radiofrequency and their combination in treatment of hepatocellular carcinoma.

Authors:  Bao-Ming Luo; Yan-Ling Wen; Hai-Yun Yang; Hui Zhi; Xiao-Yun Xiao; Bing Ou; Jing-Sheng Pan; Jian-Hong Ma
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

7.  Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C.

Authors:  Yutaka Yamanaka; Katsuya Shiraki; Kazumi Miyashita; Tomoko Inoue; Tomoyuki Kawakita; Yumi Yamaguchi; Yukiko Saitou; Norihiko Yamamoto; Takeshi Nakano; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

8.  Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma.

Authors:  Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-04       Impact factor: 3.647

9.  Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods.

Authors:  Feng Qian; Nicholas Stowe; Gerald M Saidel; Jinming Gao
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

10.  Treatment of hepatocellular carcinoma using percutaneous radiofrequency thermoablation: results and outcomes in 56 patients.

Authors:  Marc Giovannini; Vincent Moutardier; Carcline Danisi; Erwan Bories; Christian Pesenti; Jean-Robert Delpéro
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.